LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,254,561
تعداد دریافت فایل اصل مقاله7,252,630
Mohammadi, Hossein, Changizi, Vahid, Riyahi Alam, Nader, Rahiminejad, Fatemeh, Soleimani, Mehdi, Qardashi, Afsaneh. (1400). Measurement of Post-Treatment Changes in Brain Metabolites in Patients with Generalized Anxiety Disorder using Magnetic Resonance Spectroscopy. سامانه مدیریت نشریات علمی, 12(1), 51-60. doi: 10.31661/jbpe.v0i0.1224
Hossein Mohammadi; Vahid Changizi; Nader Riyahi Alam; Fatemeh Rahiminejad; Mehdi Soleimani; Afsaneh Qardashi. "Measurement of Post-Treatment Changes in Brain Metabolites in Patients with Generalized Anxiety Disorder using Magnetic Resonance Spectroscopy". سامانه مدیریت نشریات علمی, 12, 1, 1400, 51-60. doi: 10.31661/jbpe.v0i0.1224
Mohammadi, Hossein, Changizi, Vahid, Riyahi Alam, Nader, Rahiminejad, Fatemeh, Soleimani, Mehdi, Qardashi, Afsaneh. (1400). 'Measurement of Post-Treatment Changes in Brain Metabolites in Patients with Generalized Anxiety Disorder using Magnetic Resonance Spectroscopy', سامانه مدیریت نشریات علمی, 12(1), pp. 51-60. doi: 10.31661/jbpe.v0i0.1224
Mohammadi, Hossein, Changizi, Vahid, Riyahi Alam, Nader, Rahiminejad, Fatemeh, Soleimani, Mehdi, Qardashi, Afsaneh. Measurement of Post-Treatment Changes in Brain Metabolites in Patients with Generalized Anxiety Disorder using Magnetic Resonance Spectroscopy. سامانه مدیریت نشریات علمی, 1400; 12(1): 51-60. doi: 10.31661/jbpe.v0i0.1224

Measurement of Post-Treatment Changes in Brain Metabolites in Patients with Generalized Anxiety Disorder using Magnetic Resonance Spectroscopy

Journal of Biomedical Physics and Engineering
مقاله 6، دوره 12، شماره 1، فروردین و اردیبهشت 2022، صفحه 51-60    اصل مقاله (1.2 M)
نوع مقاله: Original Research
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.1224
نویسندگان
Hossein Mohammadi1؛ Vahid Changizi* 2؛ Nader Riyahi Alam3؛ Fatemeh Rahiminejad4؛ Mehdi Soleimani5؛ Afsaneh Qardashi6
1MSc, Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2PhD, Department of Technology of Radiology and Radiotherapy, Allied Medical Sciences School, Tehran University of Medical Sciences, Tehran, Iran
3PhD, Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4MD, PhD, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
5PhD, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
6BSc, Department of Radiology, Valiasr Hospital of Meshgin Shahr, Ardabil, Iran
چکیده
Background: From previous studies, we know the correlations of some brain metabolites with a generalized anxiety disorder (GAD) and its symptoms. The response of GAD patients to various treatments is not the same and finding the best treatment option for each patient takes a long period of time.
Objective: In this study, we try to examine if there is any relationship between a special treatment option and GAD patients’ response and brain metabolite correlation with anxiety level change.
Material and Methods: This study is a clinical trial type of studies. We have used proton MRS (1H-MRS) with field strength of 3 Tesla to assess whether a different treatment option makes different responses based on metabolite changes. We chose 16 patients based on Hamilton’s anxiety rate and a psychiatrist diagnosis. Patients were divided into two groups randomly. Each group took different treatments. Before treatment started, patients underwent MRS imaging and 8 weeks after treatment as well. Our study lacked a control group, and the results were analyzed by comparing the measured values of metabolites and clinical scores before and after treatment.
Results: The NAA and Cho concentration increased after treatments and Cr concentration remained constant in both groups. Both groups showed improvements in their symptoms of anxiety and also in their clinical score rates. Sertraline group showed a more increase in NAA concentration than CBT and also a more decrease in HAMA and HAMD-17 scores.
Conclusion: A simultaneously increase in NAA and Cho in both groups and a decrease in clinical anxiety levels demonstrate that NAA and Cho concentration are associated negatively with anxiety levels. In addition, both CBT and sertraline are effective in the improvement of anxiety symptoms.
کلیدواژه‌ها
Magnetic Resonance Spectroscopy؛ Generalized Anxiety Disorder؛ Sertraline؛ Cognitive Behavior Therapy؛ Dorsolateral Prefrontal Cortex؛ Brain Metabolites
سایر فایل های مرتبط با مقاله
مراجع
  1. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. European Neuropsychopharmacology. 2005;15(4):357-76. doi: 10.1016/j.euroneuro.2005.04.012. PubMed PMID: 15961293.
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision | Behavenet. [Accessed: 03-Jul-2019]. Available from: https://behavenet.com/diagnostic-and-statistical-manual-mental-disorders-fourth-edition-text-revision.
  3. Bernal M, Haro JM, Bernert S, Brugha T, et al. Risk factors for suicidality in Europe: results from the ESEMED study. Journal of Affective Disorders. 2007;101(1-3):27-34. doi: 10.1016/j.jad.2006.09.018. PubMed PMID: 17074395.
  4. Roemer L, Lee JK, Salters-Pedneault K, et al. Mindfulness and emotion regulation difficulties in generalized anxiety disorder: Preliminary evidence for independent and overlapping contributions. Behavior Therapy. 2009;40(2):142-54. doi: 10.1016/j.beth.2008.04.001. PubMed PMID: 19433145. PubMed PMCID: PMC3719394.
  5. Mantella RC, Butters MA, Dew MA, Mulsant BH, et al. Cognitive impairment in late-life generalized anxiety disorder. The American Journal of Geriatric Psychiatry. 2007;15(8):673-9. doi: 10.1097/JGP.0b013e31803111f2. PubMed PMID: 17426260.
  6. Maron E, Nutt D. Biological Markers of Generalized Anxiety Disorder. Focus. 2018;16(2):210-8. doi: 10.1176/appi.focus.16205. PubMed PMID: 32015708. PubMed PMCID: PMC6526851.
  7. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience. 2015;17(3):327. PubMed PMID: 26487813. PubMed PMCID: PMC4610617.
  8. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Structure and Function. 2008;213(1-2):93-118. doi: 10.1007/s00429-008-0189-x. PubMed PMID: 18704495. PubMed PMCID: PMC2522333.
  9. Ahola K, Virtanen M, Honkonen T, et al. Common mental disorders and subsequent work disability: a population-based Health 2000 Study. Journal of Affective Disorders. 2011;134(1-3):365-72. doi: 10.1016/j.jad.2011.05.028. PubMed PMID: 21664696.
  10. Wedegaertner F, Arnhold-Kerri S, Sittaro NA, et al. Depression-and anxiety-related sick leave and the risk of permanent disability and mortality in the working population in Germany: a cohort study. BMC Public Health. 2013;13(1):145. doi: 10.1186/1471-2458-13-145. PubMed PMID: 23413800. PubMed PMCID: PMC3698165.
  11. Hazlett-Stevens H. Psychological approaches to generalized anxiety disorder: A clinician’s guide to assessment and treatment. Springer; 2008.
  12. Shin LM, Davis FC, VanElzakker MB, et al. Neuroimaging predictors of treatment response in anxiety disorders. Biology of Mood & Anxiety Disorders. 2013;3(1):15. doi: 10.1186/2045-5380-3-15. PubMed PMID: 23915782. PubMed PMCID: PMC3750275.
  13. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders–first revision. The World Journal of Biological Psychiatry. 2008;9(4):248-312. doi: 10.1080/15622970802465807. PubMed PMID: 18949648.
  14. Buoli M, Caldiroli A, Caletti E, Paoli RA, Altamura AC. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opinion on Pharmacotherapy. 2013;14(2):175-84. doi: 10.1517/14656566.2013.759559. PubMed PMID: 23282069.
  15. Mathew SJ, Mao X, Coplan JD, Smith EL, et al. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. American Journal of Psychiatry. 2004;161(6):1119-21. doi: 10.1176/appi.ajp.161.6.1119. PubMed PMID: 15169704.
  16. Mathew SJ, Price RB, Mao X, Smith EL, et al. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biological Psychiatry. 2008;63(9):891-8. doi: 10.1016/j.biopsych.2007.09.012. PubMed PMID: 18028881. PubMed PMCID: PMC2385784.
  17. Moon CM, Kang HK, Jeong GW. Metabolic change in the right dorsolateral prefrontal cortex and its correlation with symptom severity in patients with generalized anxiety disorder: Proton magnetic resonance spectroscopy at 3 T esla. Psychiatry and Clinical Neurosciences. 2015;69(7):422-30. doi: 10.1111/pcn.12279. PubMed PMID: 25611853.
  18. Lyoo IK, Renshaw PF. Magnetic resonance spectroscopy: current and future applications in psychiatric research. Biological Psychiatry. 2002;51(3):195-207. doi: 10.1016/s0006-3223(01)01313-0. PubMed PMID: 11839362.
  19. Price RB, Eldreth DA, Mohlman J. Deficient prefrontal attentional control in late-life generalized anxiety disorder: an fMRI investigation. Translational Psychiatry. 2011;1(10):e46. doi: 10.1038/tp.2011.46. PubMed PMID: 22833192. PubMed PMCID: PMC3309492.
  20. Barker PB, Soher BJ, Blackband SJ, et al. Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference. NMR in Biomedicine. 1993;6(1):89-94. doi: 10.1002/nbm.1940060114. PubMed PMID: 8384470.
  21. Helms G. Analysis of 1.5 Tesla proton MR spectra of human brain using LCModel and an imported basis set. Magnetic Resonance Imaging. 1999;17(8):1211-8. doi: 10.1016/s0730-725x(99)00058-2. PubMed PMID: 10499683.
  22. Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HB. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magnetic Resonance Imaging. 1993;11(1):107-18. doi: 10.1016/0730-725x(93)90418-d. PubMed PMID: 8423713.
  23. Meyrhoff DJ, MacKay S, Constans JM, Norman D, et al. Axonal injury and membrane alterations in Alzheimer’s disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Annals of Neurology. 1994;36(1):40-7. doi: 10.1002/ana.410360110.
  24. Abdallah CG, Coplan JD, Jackowski A, et al. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. European Neuropsychopharmacology. 2013;23(4):276-84. doi: 10.1016/j.euroneuro.2012.05.009. PubMed PMID: 22739126. PubMed PMCID: PMC3473175.
  25. Brewer GJ, Wallimann TW. Protective effect of the energy precursor creatine against toxicity of glutamate and β-amyloid in rat hippocampal neurons. Journal of Neurochemistry. 2000;74(5):1968-78. doi: 10.1046/j.1471-4159.2000.0741968.x. PubMed PMID: 10800940.
  26. Andres RH, Ducray AD, Schlattner U, et al. Functions and effects of creatine in the central nervous system. Brain Research Bulletin. 2008;76(4):329-43. doi: 10.1016/j.brainresbull.2008.02.035. PubMed PMID: 18502307.
  27. New AS, Hazlett EA, Newmark RE, et al. Laboratory induced aggression: a positron emission tomography study of aggressive individuals with borderline personality disorder. Biological Psychiatry. 2009;66(12):1107-14. doi: 10.1016/j.biopsych.2009.07.015. PubMed PMID: 19748078. PubMed PMCID: PMC2788117.
  28. Hoerst M, Weber-Fahr W, Tunc-Skarka N, et al. Metabolic alterations in the amygdala in borderline personality disorder: a proton magnetic resonance spectroscopy study. Biological Psychiatry. 2010;67(5):399-405. doi: 10.1016/j.biopsych.2009.09.030. PubMed PMID: 19931853.
  29. Gemar MC, Segal ZV, Mayberg HS, et al. Changes in regional cerebral blood flow following mood challenge in drug-free, remitted patients with unipolar depression. Depression and Anxiety. 2007;24(8):597-601. PubMed PMID: 17133439. doi: 10.1002/da.20242.
  30. Yue Q, Liu M, Nie X, Wu Q, Li J, et al. Quantitative 3.0 T MR spectroscopy reveals decreased creatine concentration in the dorsolateral prefrontal cortex of patients with social anxiety disorder. Plos One. 2012;7(10):e48105. doi: 10.1371/journal.pone.0048105. PubMed PMID: 23110183. PubMed PMCID: PMC3479123.
  31. Amenta F, Tayebati SK. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Current Medicinal Chemistry. 2008;15(5):488-98. doi: 10.2174/092986708783503203. PubMed PMID: 18289004.
  32. Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nature Reviews Neuroscience. 2005;6(1):48-56. doi: 10.1038/nrn1588. PubMed PMID: 15611726.
  33. Ferguson KJ, MacLullich AM, Marshall I, Deary IJ, et al. Magnetic resonance spectroscopy and cognitive function in healthy elderly men. Brain. 2002;125(12):2743-9. doi: 10.1093/brain/awf278. PubMed PMID: 12429601.
آمار
تعداد مشاهده مقاله: 1,446
تعداد دریافت فایل اصل مقاله: 534


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب